Bioavailable prodrugs of androgenic steroids and related method
US6740646B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 16, 2002 |
| Grant date | May 25, 2004 |
| Priority date | — |
| Expiry date | Jan 16, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/573
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound is provided for increasing the concentration of a parent androgen in a subject in vivo. The parent androgen has a skeletal structure including a 1 position and a 17 position, a 17&bgr;-hydroxy group comprising a 17&bgr;-hydroxy oxygen appended to the 17 position, and a 17&bgr;-hydroxy hydrogen appended to the 17&bgr;-hydroxy oxygen. The compound includes a substrate having the skeletal structure of the parent androgen. It includes a 1 position and a 17 position corresponding to the 1 and 17 positions respectively of the parent androgen. The substrate has a carbon—carbon double bond at the 1 position. The compound also has a promoiety appended to the 17&bgr;-hydroxy oxygen of the substrate as a substitute for the 17&bgr;-hydroxy hydrogen of the parent androgen. The promoiety includes, and preferably consists of, an alkylcarbonate ester. A related method also is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.